Biomea Fusion Announces Updated Timing for BMF-650 Phase I Topline Results

What Happened
On September 22, 2026, Biomea Fusion, Inc. (BMEA) filed an 8-K (Item 8.01) to update the anticipated timing for topline results from its ongoing Phase I GLP-131 trial of BMF-650. The company said topline data from the trial in obese, otherwise healthy volunteers are now expected in October 2026. The filing was signed by Michael J.M. Hitchcock, Interim Chief Executive Officer.

Key Details

• Filing date: September 22, 2026 (Form 8-K, Item 8.01 Other Events).
• Trial: Phase I GLP-131 of BMF-650 in obese, otherwise healthy volunteers.
• Timing update: Topline results are now expected in October 2026.
• Corporate signatory: Michael J.M. Hitchcock, Interim CEO and Director.

Why It Matters
This timing update sets the next near-term clinical catalyst for Biomea Fusion—topline Phase I data could affect investor expectations about the drug’s development progress. Investors tracking the company should note the revised October 2026 milestone for potential news flow; this filing does not report financial results or executive changes beyond the signing by the interim CEO.